Clinical trials: Hep A
Hepatitis C
Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC)
The overall aim of this study is to evaluate the prevalence of cognitive impairments and brain anomalies in Chronic Hepatitis C infected individuals and to investigate likely changes in cognition and brain structure and function…
- Trial name
- CICHepC (NCT02745132)
- Testing
- Neuropsychological evaluation and Brain MRI
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Hepatitis B, Chronic Hepatitis B
Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers
This is an open-label, randomized, multi-part study to evaluate the relative oral bioavailability of a tablet formulation of AL-3778 (formerly NVR 3-778) administered under fasted and fed conditions (Parts 1 and 2) and the…
- Conditions
- Hepatitis B, Chronic Hepatitis B, Viral Hepatitis B
- Trial name
- NCT03032536
- Testing
- AL-3778, Entecavir, Tenofovir disoproxil fumarate
- Where
- 2 sites in New Zealand
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Viral Hepatitis
Continuing Medical Education to Improve Knowledge of Viral Hepatitis B-C in Primary Healthcare Workers
The purpose of study is identifying the effectiveness of 'continuing medical education' (CME) to primary healthcare worker to improve knowledge about viral hepatitis B-C
- Trial name
- NCT05207163
- Testing
- Continuing medical education
- Where
- Vietnam
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Pham Ngoc Thach University of Medicine
Hepatitis C, Chronic
Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)
Based on previous experience with peginterferon alfa-2b/ribavirin in combination with boceprevir, the combination with peginterferon alfa- 2a/ribavirin and boceprevir is expected to be safe and well tolerated.
- Trial name
- NCT00845065
- Testing
- Boceprevir, Peginterferon alfa-2a, Ribavirin
- Volunteers
- 202 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
TD-6450 SAD and MAD in Healthy Subjects
This study consists of two parts, Parts A and B. Part A is a single ascending dose (SAD) study in healthy subjects. Part B is a multiple ascending dose (MAD) study in healthy subjects.
- Trial name
- NCT02022306
- Testing
- TD-6450
- Where
- United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Cytomegalovirus Infection, Hepatitis C
Impact of Cytomegalovirus (CMV) Replication Over Hepatitis C Recurrence in Liver Transplant Recipients
The relationship between cytomegalovirus infection and recurrence of hepatitis C in liver transplant recipients remains controversial.
- Trial name
- VHENUS (NCT01473849)
- Where
- 13 sites in Spain
- Volunteers
- 179 people
- Sponsor
- Sociedad Española de Trasplante Hepático
Hepatitis B, Chronic
Effect of Entecavir Versus Tenofovir on HBV DNA Level in Peripheral Blood Mononuclear Cells
Liver disease associated with persistent hepatitis B virus (HBV) infection remains an important public health problem with significant morbidity and mortality.
- Trial name
- NCT05168293
- Testing
- Detection of HBV-DNA in Peripheral Blood Mononuclear cells
- Volunteers
- 100 people
- Sponsor
- Assiut University
Cholangitis, Sclerosing, Hepatitis, Autoimmune
Selected Mesenchymal Stromal Cells to Reduce Inflammation in Patients With PSC and AIH
MERLIN is an adaptive, single arm, multi-centre, phase IIa multi-disease clinical trial. It is designed to: i) Determine dose safety of ORBCEL-C™ (selected Mesenchymal stromal cells derived from human umbilical cord) ii) Evaluate…
- Trial name
- Merlin (NCT02997878)
- Testing
- Orbcel-C
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- University of Birmingham
Liver Dysfunction, Immune Suppression
Optimizing HBV Management During Anti-CD20 Antibodies
Hepatitis B virus (HBV) reactivation is common during anti-CD20 containing chemotherapy, even in HBsAg-negative patients with only prior HBV exposure.
- Conditions
- Liver Dysfunction, Immune Suppression, Hepatitis B
- Trial name
- NCT03155984
- Testing
- Anti-CD20 antibody
- Where
- Hong Kong
- Volunteers
- 83 people
- Sponsor
- The University of Hong Kong
Living Donor Liver Transplantations With Anti-HBc (+) Grafts
Long-term Outcomes of Living Donor Liver Transplantations With Anti-HBc (+) Grafts in Pediatric Patients
The goal of this observational study is to compare in anti-HBc (+) grafts/ anti-HBc (-) grafts. The main question it aims to answer is the long-term efficacy of active vaccination and graft/patient outcomes of anti-HBc (+) grafts…
- Trial name
- NCT06290726
- Volunteers
- 204 people
- Sponsor
- Chang Gung Memorial Hospital
Hepatitis C, Chronic
A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response
This study will evaluate the efficacy and safety of peginterferon alfa-2a 40KD + ribavirin combination therapy given for 24 weeks versus 48 weeks in patients with chronic hepatitis C, genotype 2/3.
- Trial name
- NCT00623428
- Testing
- peginterferon alfa-2a, Ribavirin
- Where
- 101 sites in United States, Australia and 8 more
- Volunteers
- 235 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs
The purposes of this Phase 1/2 study are to examine the safety, tolerability, and antiviral activity of ISIS 14803, when given in combination with peginterferon alfa and ribavirin, to patients who either failed to have at least a…
- Trial name
- NCT00062816
- Testing
- ISIS 14803, peginterferon alfa, ribavirin
- Where
- 25 sites in United States
- Volunteers
- 22 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
HBV, HCV
Non-interventional Study to Assess the Number of People With Untreated/Unknown HBV + HDV and HCV in South-East Austria
The HEAL-S study is a non-interventional study with retrospective data analysis. It consists of two parts. First a retrospective analysis based on nucleic acid testing (NAT) results will be performed.
- Conditions
- HBV, HCV, HDV, Coinfection
- Trial name
- HEAL-S (NCT06834178)
- Where
- Austria
- Volunteers
- 100 people
- Sponsor
- Vanessa Stadlbauer-Koellner, MD
Chronic Hepatitis B
Performance of Novel Simplified Score for Chronic Hepatitis B Treatment Eligibility in Thailand
International and national guideline for chronic hepatitis B (HBV) infection treatment recommend initiated antiviral in high HBV viral loads patients with significant liver inflammation and significant liver fibrosis.
- Trial name
- NCT05295914
- Testing
- TREAT-B score
- Where
- Thailand
- Volunteers
- 600 people
- Sponsor
- Mahidol University
Hepatitis C
Strategic Transformation of the Market of HCV Treatments
This is a Phase II/III, multicenter, multi-country, trial to assess the efficacy, safety, tolerance and pharmacokinetics of sofosbuvir plus ravidasvir for the treatment of HCV infection.
- Trial name
- STORM-C-1 (NCT02961426)
- Testing
- sofosbuvir + ravidasvir
- Where
- 13 sites in Malaysia, Thailand
- Volunteers
- 603 people
- Sponsor
- Drugs for Neglected Diseases
Male Infertility, HCV
Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters
Hepatitis C virus is commona viral infection. Direct-acting antiviral (DAA) oral drugs has been used in treatment of HCVs. the effect of these drugs on male infertility is still under investigation.
- Trial name
- NCT05616598
- Testing
- Sofosbuvir +daclatasvir+ simeprevir+Ribavirin
- Where
- 2 sites in Egypt
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Benha University
Hepatitis C, Chronic
Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in the Prison Setting
SHARP-P is an observational cohort study investigating the effect of direct-acting antiviral (DAA) therapy and reinfection in people with chronic hepatitis C virus (HCV) and recent injecting drug use.
- Trial name
- SHARP-P (NCT03740906)
- Where
- Australia
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
Chronic Hepatitis B
A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection
The purpose of this clinical research study is to find out whether a combination of entecavir (ETV) plus tenofovir (TNF) works better against Hepatitis B virus than adefovir (ADV) added to continuing lamivudine (LVD) therapy in…
- Trial name
- NCT00605384
- Testing
- Entecavir + Tenofovir, Adefovir + continuing Lamivudine
- Where
- 29 sites in United States, Belgium and 4 more
- Volunteers
- 4 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis B
HBsAg Decline After Pegylated-interferon-α in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance
This study proposes to compare the effect of 48 weeks exposure to pegylated interferon alpha vs. nucleoside analogue (NA) on hepatitis B e antigen (HBeAg) seroconversion and HBsAg levels in nucleoside analogue controlled…
- Trial name
- NCT01769833
- Testing
- PEG-interferon-Alfa-2A, Nucleosides
- Where
- South Korea
- Volunteers
- 144 people
- Sponsor
- Pusan National University Hospital
Chronic Hepatitis B Infection
The Changes of CD4+T Cells Frequency and Function During Antiviral Therapy
Pegylated interferon α-2a(Peg-IFN-α) not only inhibit viral replication, but also play an important role in immune regulation, while Nucleoside analog(ue) drugs only inhibit viral replication.
- Trial name
- NCT03209011
- Testing
- Peginterferon Alfa-2a
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Yao Xie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.